Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As DC Speculates on Democrats in 2009, Some Old FDA Hands Come Into View

This article was originally published in RPM Report

Executive Summary

No matter who wins, the 2008 Presidential election means there will be widespread personnel changes across key federal health agencies. Two ex-FDA officials look particularly ready to resurface should the Democrats take back the White House.

You may also be interested in...



Prioritizing Health Care: Reform Gains Early Momentum

Health care reform advocates think the stars are aligned for a major push toward universal coverage under President-elect Barack Obama. They aren’t about to let the free-falling economy get in the way.

Building the Right Foundation: An Interview with Mark McClellan

The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.

Preparing for Health Care Reform: Why Big Pharma Thinks it Can Avoid Another "Hillarycare"

Should a Democrat take the White House next January, top pharmaceutical executives expect a serious push for health care reform. The prospect of a health care reform debate triggers the specter of a single-payor, government-run system with price controls. But Democrats are singing a surprisingly soothing tune.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel